The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Since interferon medication is quickly broken down by a person's circulatory and digestive systems, its potency is typically short-lived. By resisting rapid breakdown, Nautilus Biotech's newly engineered interferon-alpha drug, Belerofon, shows promise in increased effectiveness against Hepatitis C. Now in a Phase I study, we will soon learn of Belerofon's safety and tolerability.
Continue reading »The results from the Phase I study with XTL-6865, a new compound being tested in patients with chronic Hepatitis C, are promising. In addition to the detailed outcome of this study, you'll learn how XTL-6865 may become a viable treatment option for patients with Hepatitis C undergoing liver transplantation, or for individuals with chronic Hepatitis C who have low viral loads.
Continue reading »Studies show that up to one in ten mothers infected with the Hepatitis C virus are likely to transmit the infectious disease to their children. Learn how much the risk of transmission increases when the mother is also infected with HIV.
Continue reading »Eighty-five percent of HCV patients develop chronic Hepatitis C. The remaining 15 percent have acute Hepatitis C, which spontaneously resolves within weeks or months. Learn how the health of your immune system determines whether the virus progresses to advanced liver disease and what you can do to help support your immune system.
Continue reading »A new drug called Infergen is opening new doors for people infected with the Hepatitis C virus who are not responding to standard treatment. Learn why this treatment option is recommended for non-responders, and other key information to share with your physician in determining whether Infergen may be right for you.
Continue reading »According to the Centers for Disease Control and Prevention (CDC), vaccination programs for Hepatitis A and B have helped decrease the rate for new acute hepatitis infections. Despite this good news, the American Liver Foundation (ALF) points out that chronic Hepatitis C infection rates have not followed suit and are actually increasing. Learn what is causing the concern behind the ALF's response, and how the cost of treating Hepatitis C impacts our health care system.
Continue reading »Night sweats are a common symptom of chronic Hepatitis C infection. Though Western medicine has neither a concrete explanation nor a solution, Traditional Chinese Medicine has ways of dealing with this uncomfortable symptom. Learn more about the causes of night sweats and what you can do to manage and minimize their impact.
Continue reading »More than 60% of people who die as a result of the Hepatitis C virus (HCV) have served in our country's military. A recent study conducted by the Veterans Health Administration determined the infection rate for veterans living with HCV is five times greater than the general population. Learn why veterans are an at-risk group for carrying HCV and the value of being tested immediately.
Continue reading »Immediately upon sending the most recent Research and Treatment News Update earlier today, we learned of the unfortunate news that New York Assemblyman Kenneth Zebrowski passed away Sunday morning. Join us in sending our heartfelt condolences to the Assemblymen's family during this difficult time. In addition to learning more about Mr. Zebrowski's public service career, read on to find information regarding funeral arrangements for those who wish to pay their respects to this honored politician.
Continue reading »Roche will soon test a new treatment strategy in Hepatitis C patients who have a high viral load and are overweight. Individuals with hard-to-treat characteristics will be particularly interested in the result of this trial examining the effect of combining different levels of PEGASYS and ribavirin.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
